SNS-301 Monotherapy in High Risk MDS and CMML
NCT04217720
·
clinicaltrials.gov ↗
PHASE2
Phase
WITHDRAWN
Status
INDUSTRY
Sponsor class
Stopped
Sponsor decision
Conditions
Myelodysplastic Syndromes
Chronic Myelomonocytic Leukemia (CMML)
Interventions
DRUG:
SNS-301
Sponsor
Sensei Biotherapeutics, Inc.